Biotech partnership spotlights development plans for a Parkinson's therapeutic. Readers receive an industry-focused briefing on strategic intent and capabilities.
Key Takeaways
- FDA cleared an IND for the investigational SER-252, allowing clinical studies to proceed
- Gannet BioChem will provide process development, scale-up and manufacturing support for SER-252
- Serina's POZ Platform is designed to improve therapeutic delivery, efficacy and safety